Next AGM will be interesting. Doubt many directors will be left after wounded shareholders act. Clearly one director probaby wishes today he wasn't there also given his $100k latest investment has turned into $50k with these results. CEO replaced already so he'll probably get some honeymoon time at least.
$$$ they should definitely spend should be on people who can actually put together a trial, assuming the current cashflow is adequate to keep things ticking along for more trials. Did they go inside for the trial structure or external consultants anyway?
Assumed any R&D is dead for a long time also.
On to bigger and better [non biotech] things now.
PXS Price at posting:
17.5¢ Sentiment: Hold Disclosure: Held
